Keep up to Date and Stay Informed

Sign up for email alerts to receive company updates including press releases, filings and special announcements straight to your inbox.

Sign me up for:

Press Releases
Annual/Quarterly Reports
Current Reports
Insider Transactions
Proxy Information
All Filings

Latest Financial Results

Q3 2022

Quarter Ended Sep 30, 2022

Latest Annual Filing

Fiscal Year Ended Dec 31, 2021

View Filing

Stock Information

Company Overview

Acurx Pharmaceuticals is a publicly held clinical stage biopharmaceutical company focused on developing new antibiotics for difficult to treat infections. Acurx's approach is to develop antibiotic candidates that target the DNA polymerase IIIC enzyme and its R&D pipeline includes early stage antibiotic candidates that target other Gram-positive bacteria, including Methicillin-Resistant Staphylococcus aureus (MRSA), Vancomycin- Resistant Enterococcus (VRE) and Penicillin-Resistant Streptococcus pneumoniae (PRSP).

ID Week Presentation (October 2022) Development Update on Ibezapolstat for the Treatment of Clostridioides difficile infection: Focus on the Microbiome

ID Week Presentation (October 2022) Development Update on Ibezapolstat for the Treatment of Clostridioides difficile infection: Focus on the Microbiome

Download ID Week Presentation (October 2022) Development Update on Ibezapolstat for the Treatment of Clostridioides difficile infection: Focus on the Microbiome

Leadership

Having accumulated decades of collective experience across a variety of fields, our leadership team is the source of our success.

Investor Contact Information

Company

Acurx Pharmaceuticals, Inc.
259 Liberty Avenue
Staten Island, NY 10305

Investor Relations

In-Site Communications
Lisa Wilson